SCHEMBL4696246

SCHEMBL4696246

N#Cc1nc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2)nc1OCCN1CCCC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 3/20 0.48
CTSS P25774 3/20 0.45
CTSK P43235 1/20 0.45
EGLN2 Q96KS0 2/20 0.41
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 2/20 0.39
AKT1 P31749 1/20 0.39
AKT2 P31751 1/20 0.39
USP8 P40818 1/20 0.38
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
IDH1 O75874 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4695659 0.85 USP8 (0.40) SGK1USP8ALDH1A1HRH3CYP1A2
SCHEMBL5520596 0.82 HRH3 (0.54) HRH3
SCHEMBL4690341 0.78 SIGMAR1 (0.47) MEN1KMT2AKDM4EALDH1A1HTT
SCHEMBL14545311 0.77 CNR1 (0.40) KDM4EUSP8ALDH1A1GAAHPGD
SCHEMBL4694032 0.76 CHRM1 (0.38) KDM4EALDH1A1GAAHPGDHTT
SCHEMBL4747833 0.74 USP8 (0.57) MEN1KMT2AKDM4EUSP8ALDH1A1
SCHEMBL5521872 0.71 USP8 (0.43) KDM4EUSP8ALDH1A1GAAHPGD
SCHEMBL4695206 0.70 CNR1 (0.46) MEN1KMT2AKDM4EUSP8ALDH1A1
SCHEMBL14545380 0.70 CNR1 (0.45) POLBKDM4E
SCHEMBL14545547 0.68 KDM4E (0.50) POLBKDM4EUSP8ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 SGK1 4590/4885CTSS 1578/4885CTSK 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.